Abstract:
본 발명은 감초 추출물을 유효성분으로 함유하는 환경호르몬에 의한 독성 방어용 조성물에 관한 것으로, 본 발명의 감초 추출물은 유방암 세포 라인인 MCF-7 세포에서 비스페놀 에이(Bisphenol A)의 독성으로 인한 세포의 이상증식을 저해하고, 생체내 실험(In vivo)에서 비스페놀 A에 의한 독성인 자궁과 질 상피세포의 이상증식을 저해함으로써 BPA 독성 감소 효과를 나타내므로, 감초 추출물을 함유하는 조성물은 환경호르몬에 의한 독성의 치료 및 예방용 조성물로써 의약품 또는 건강기능식품에 유용하게 이용될 수 있다.
Abstract:
PURPOSE: Provided is a composition for preventing and treating disease associated with inhibition of gap junctional internal cellular communication and unbalance of Homeostasis, which composition contains Ulmus macrocarpa HANCE extract and effectively recovers the inhibition of gap junctional internal cellular communication and the unbalance of Homeostasis. It is therefore, used for manufacture of medicaments, processed foods, functional foods, beverages and drinks. CONSTITUTION: A composition for preventing and treating disease associated with inhibition of gap junctional internal cellular communication and unbalance of Homeostasis is characterized by containing, as an active ingredient, an effective amount of Ulmus macrocarpa HANCE extract or its active fraction, and pharmaceutically acceptable carriers. The extract is obtained by extracting Ulmus macrocarpa HANCE with 60% ethanol solution or hot water.
Abstract:
PURPOSE: A composition containing an extract of Phellinus linteus as an effective component is provided which effectively recovers the inhibition of gap junctional intercellular communication and the unbalance of homeostasis and thus can be used for prevention or treatment of disease associated therewith. CONSTITUTION: Phellinus linteus is extracted in ethanol or hot water under high pressure and a pharmaceutical composition for prevention or treatment of disease associated with the inhibition of gap junctional intercellular communication and the unbalance of homeostasis contains the Phellinus linteus extract and a pharmaceutically acceptable carrier. The effective dose of the pharmaceutical composition is 15 to 170mg/kg body weight/day. The disease associated with the inhibition of gap junctional intercellular communication and the unbalance of homeostasis is nervous system disorders containing diabetics, Charcot-Marie-Tooth disease type 1, blood related disorders containing spermatogenesis disorders, blood related disorders containing hypertension or epilepsia.
Abstract:
A method for differentiating or proliferating an adult stem cell is provided to promote the differentiation of mesenchymal stem cells derived from cord blood into neurons and increase the proliferation of the cells by culturing the stem cells in a patterned polydimethylsiloxane(PDMS). And a cell therapeutic agent comprising the cells obtained by the method above is provided to be effective for treating spinal cord injury and nerve injury because of the obtained cells' constant directivity of length increase. A method for proliferating an adult stem cell or a method for differentiating the adult stem cell into a neuron, a bone cell, a fat cell, a muscular cell or a fibroblast is characterized in that a patterned PDMS having a pattern size of 1-4 micrometer(s) is used as a scaffold. A cell therapeutic agent comprises the stem cell obtained by the method and fixed on the patterned PDMS scaffold. Further, the adult stem cell is derived from breast, bone marrow, cord blood, blood, liver and intestines, skin, stomach and intestines, placenta and womb.
Abstract:
A DNA chip for determining a pharmaceutical drug with hepatotoxicity is provided to improve rapidness and accuracy of determination by specifically detecting changes of gene expression patterns upon administration of a pharmaceutical drug with hepatotoxicity. A DNA chip for determining a pharmaceutical drug with hepatotoxicity comprises (i) a gene probe capable of specifically binding to a gene of which expression pattern is changed when a pharmaceutical drug with hepatotoxicity is administered, (ii) a linker containing oligo(dT)15, -(CH2)6- and amine group, sequentially and being linked to the 5'-terminal of the gene probe through the thymine site, and (iii) a solid substrate having an aldehyde group on the surface and being linked to the linker through Schiff's base binding between an amine group of linker and aldehyde group of the substrate, wherein the gene probe has the nucleotide sequence selected from SEQ ID NO:1 to SEQ ID NO:54.
Abstract translation:提供用于测定具有肝毒性的药物的DNA芯片,以通过特异性地检测在施用具有肝毒性的药物的基础表达模式的变化来提高测定的快速性和准确性。 用于测定具有肝毒性的药物的DNA芯片包括(i)当施用具有肝毒性的药物时,能够特异性结合表达模式改变的基因的基因探针,(ii)含有寡核苷酸(dT)15 , - (CH2)6-和胺基,并通过胸腺嘧啶位点连接到基因探针的5'末端,和(iii)在表面上具有醛基并与连接体连接的固体底物 通过基团的连接基团和底物的醛基之间的希夫碱基结合,其中基因探针具有选自SEQ ID NO:1至SEQ ID NO:54的核苷酸序列。
Abstract:
본 발명은 제대혈(탯줄혈액)에서 성체줄기세포인 다분화능 줄기세포(Multipotent Stem Cell) 및 이를 함유하는 폐쇄성 동맥질환에 의한 허혈성 괴사질환에 대한 세포치료제에 관한 것으로서, 상세하게는 본 발명의 다분화능 줄기세포는 성체줄기세포임에도 불구하고 골형성 세포 또는 신경세포로 분화하는 능력을 가지고 있어서 대퇴부의 동맥순환 정체가 말초순환장애를 일으킴으로서 미세 혈관계의 조직을 붕괴시켜 허혈성 괴사를 야기하는 질병 뿐만 아니라 뇌경색, 심근경색, 당뇨의 후유증으로 오는 사지 말단의 괴사 등 허혈성 질병등의 치료에 유용하다. 제대혈, 다분화능 줄기세포, 허혈성 괴사
Abstract:
본 발명은 갭 결합을 통한 세포간 신호전달 억제제의 투여시 발현되는 유전자와 특이적으로 결합할 수 있는 유전자 탐침을 포함하는 DNA 칩, 전기 DNA 칩의 제조방법, 전기 DNA 칩을 포함하는 갭 결합을 통한 세포간 신호전달 억제제 선별용 키트 및 전기 키트를 사용하여 갭 결합을 통한 세포간 신호전달 억제제를 선별하는 방법에 관한 것이다. 본 발명의 갭 결합을 통한 세포간 신호전달 억제제 선별용 DNA 칩은 216 내지 477개의 뉴클레오티드로 구성되고, 갭 결합을 통한 세포간 신호전달 억제제에 의해 발현유도되는 유전자와 특이적으로 결합할 수 있는 유전자 탐침; 올리고(dT) 15 , -(CH 2 ) 6 - 및 아민(amine)기를 순차적으로 포함하고, 전기 유전자 탐침의 5' 말단이 올리고(dT) 15 의 3'말단부위에 연결된 링커; 및, 표면에 알데히드가 부착되고, 전기 링커의 아민기가 표면의 알데히드기와 시프염기(Schiff's base) 반응을 통해 연결된 고체기판을 포함한다. 본 발명의 갭 결합을 통한 세포간 신호전달 억제제 선별용 키트는 세포를 손상시키거나 또는 유전적으로 변형시킬 가능성이 있는 물질을 사전에 선별할 수 있으므로, 여러가지 물질의 안전성 검사에 널리 활용될 수 있을 것이다.
Abstract:
The present invention relates to a DNA chip which comprises probes hybridizable to genes expressed when individuals are dosed with peroxisome proliferator, a process for preparing the DNA chip, a screening kit comprising the said DNA chip, and a method for screening of peroxisome proliferator by using the said kit. The DNA chip for screening of peroxisome proliferator comprises: a probe of 121 to 587 nucleotides hybridizable to a gene expressed when individuals are dosed with peroxisome proliferator; a linker consisting of oligo(dT) 15 , -(CH 2 ) 6 - and amine residue in a sequential order, whose 5' end is bonded to the 3' end of the said oligo(dT) 15 ; and, a solid substrate attached to aldehyde residue which is bonded to the amine residue of the linker via Schiff's base reaction. The screening kit of the invention can be readily used for the selection of peroxisome proliferators which show peroxisome proliferating activity to induce abnormal cellular responses, which makes possible its practical application in the safety test of various materials.